Myriad Genetics, Inc. (NASDAQ:MYGN)
CAPS Rating:
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Growing the love for investing
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
MYGN must invest in new areas otherwise its stock declines. others are moving: examination "early Cdt for lung cancer and a new blood test for cancerof Oncimmune for exemple. Without innovation only speculation made by the robbers of the people.Does MYGN want to accept the challenge?
Myriad Genetics Earnings In Retrospect: Down 26.95% In Last 38 Days